circle-image

Short

Trend Resistance

Uptrend Above: 24160

Bull Market Above: 24330
circle-image

Term

Trend Point Acts

Trend Point: 24140

My PCR: 0.91
384 Range 54

Bear Market Signal

circle-image

View

Trend Suport

Down Below: 24120

Bear Market Below: 24000
Short Term View Historic Data

Nifty View Tomorrow: Tuesday 30 Jun 2026

Day Close

23946
Day High

24120
Day Low

23924
Day Avg

23997
29 Jun 2026
5 SMA

23990
10 SMA

24006
20 SMA

23674
50 SMA

23846
200 SMA

24882
5 EMA

23966
10 EMA

23974
20 EMA

23800
50 EMA

23886
Tomorrow
Resist 2

24170
Resist 1

24060
Mid Point

23960
Suport 1

23860
Suport 2

23780
52W High

26373
52w Low

22182
52w Down

9.2%
52w Up

7.95%
Panic View
Resist 2

24390
Resist 1

24225
Mid Point

23980
Suport 1

23735
Suport 2

23610
5d High

24261
5d Low

23784
10d High

24261
10d Low

23784
Days High & Low 20d High

24261
20d Low

23070
50d High

24601
50d Low

23070
All Avg

23887
FFTH

24102
FTTL

23943
TTTH

24102
TTTL

23705
High & Low Avg TTFH

23977
TFFL

23580
High Avg

24060
Low Avg

23743
All Avg

23902
Nifty Historic Prediction Data

Nifty Last Five Days Moves

SNo. Date Day Close Day High Day Low 5 DMA 10 DMA 20 DMA 50 DMA 200 DMA
1 29 Jun 2026 23946 24120 23924 23990 24006 23674 23846 24882
2 25 Jun 2026 24056 24261 24039 24003 23973 23654 23851 24886
3 24 Jun 2026 24021 24090 23789 24026 23884 23646 23847 24889
4 23 Jun 2026 23824 24135 23784 24038 23803 23641 23848 24892
5 22 Jun 2026 24102 24168 24073 24071 23745 23651 23847 24895
Nifty Historic Data And Moving Avg

Go Back

Innova Captab Ltd is an integrated pharmaceutical company in India with a presence across the pha...

Posted: 03 Nov 2024

Innova Captab Ltd is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Since our inception in 2006 with a small base, we have grown strength to strength and for last more than 15 years, we are catering to top Indian pharmaceuticals companies including 10 of the top 10, and 14 of the top 15. We have license to manufacture products through two state of the art manufacturing facilities while maintaining WHO-GMP, EU-GMP and other major registrations. With the support of our world class manufacturing facilities and a reliable supply value chain, we are continuously thriving to maintain highly efficient operations. The foundation of our Company is our in-house research and development (R&D). which helps to focus on to build an increasingly complex product portfolio and attract and retain customers. We proudly possess a strong team of 1000+ employees. As a responsible corporate entity, we are been continuously endeavouring to comply with Environmental, Social & Governance compliance requirements covering the aspects of Legal compliance, ethics & business conduct, quality & patient safety, human rights, labour and employment, health safety and well-being of employees, sustainability & environmental responsibility, quality management system. Our business includes CDMO business providing research, product development and manufacturing services. We were third fastest growing CDMO in terms of Operating Income over the period Fiscal 2019 to Fiscal 2023 and positioned our Company to benefit from the growth in the CDMO market by developing strong R&D and manufacturing operations for our customers to support their domestic sales and exports to certain markets. Fourteen of the top fifteen Indian pharmaceutical companies that CRISIL Research identified as the largest players in the domestic formulation market in Fiscal 2023 have been a part of our customer base. Our Capabilities World class manufacturing facilities in Baddi, Himachal Pradesh and Our manufacturing facilities have good manufacturing practices certifications in conformity with the format recommended by WHO-GMP, EU-GMP and many other international authorities. Strong R&D focus to build an increasingly complex product portfolio and attract and retain customers Our CDMO product portfolio spans across both acute and chronic therapeutic areas Leading presence and one of the fastest growing CDMOs in the Indian pharmaceutical formulations market Well established relationships with our marquee CDMO customer base Our strength in CDMO sphere includes: Our comprehensive CDMO formulation capabilities allow us to offer our customers multiple dosage forms, including oral solids, oral liquids, dry syrups and injectables, as well as more complex delivery forms such as modified and sustained release forms and tablets in capsules. We manufacture products that are in all the top ten therapeutic areas by sales in the Indian formulation market in Fiscal 2023 as identified by CRISIL Research. We manufacture products across some of the key therapeutic areas. Our operational track record in successful delivery of products, R&D, quality and technical standards and productivity Strong R&D and manufacturing operations for our customers to support their domestic sales and exports to certain markets. Our R&D laboratory is equipped with the entire suite of necessary equipment for the development of solid oral and liquid dosage forms Domestic Branded Generics Our Branded Generics business consists of the development, manufacture and distribution of generic formulation products, which are marketed and distributed in India under our own brand names through online and offline channels. Our branded generic products are generic medicines for which the patents have expired, that are sold directly to our distributors, stockists & retailers. We sell our domestic branded generic products through our pan-Indian network of distributors, stockists and pharmacies. Our generic drug products are also available online through various e-commerce pharmacy sites. We have developed a diversified branded generics product portfolio including Tablets, capsules, dry syrups, dry powder injection, ointments and liquid orals

Market Bits

"In investing, what is comfortable is rarely profitable." — Robert Arnott

Be prepared to invest in a down market and to "get out" in a soaring market, as per the philosophy of Warren Buffett.